Comprehensive Study Confirms No Link Between Maternal mRNA COVID-19 Vaccination and Childhood Neurodevelopmental Disorders

Research presented at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting has definitively concluded that receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not associated with autism or other developmental disorders in children. These pivotal findings offer robust, new data regarding the long-term health trajectories of children whose mothers received vaccination around the periconceptional period and throughout gestation, providing crucial reassurance for expectant parents and public health authorities worldwide.

The Urgent Need for Clarity: Addressing Perceptions and Protecting Maternal-Fetal Health

From the earliest stages of the COVID-19 pandemic, pregnant individuals faced unique vulnerabilities. Data rapidly emerged indicating that pregnant people infected with SARS-CoV-2 were at an increased risk of severe illness, including intensive care unit admission, mechanical ventilation, and even death, compared to non-pregnant individuals of reproductive age. Furthermore, COVID-19 in pregnancy was linked to adverse obstetric outcomes such as preterm birth, preeclampsia, and stillbirth. The imperative to protect this population became a paramount public health priority.

When COVID-19 vaccines became available in late 2020 and early 2021, a rapid scientific effort commenced to assess their safety and efficacy in pregnant and lactating individuals. Initial data, primarily from vaccine registries and observational studies, quickly established the short-term safety of mRNA vaccines during pregnancy, demonstrating no increased risk of miscarriage, congenital anomalies, or other immediate adverse events. Organizations like the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and the World Health Organization (WHO) swiftly moved to recommend COVID-19 vaccination for pregnant individuals, emphasizing its critical role in safeguarding both maternal and infant health. In the United States, two primary types of COVID-19 vaccines are recommended for adults, including pregnant individuals: the messenger ribonucleic acid (mRNA) vaccine and a protein subunit vaccine. Both have been deemed safe and effective across all stages of pregnancy.

Despite this robust initial evidence, persistent misinformation and lingering public skepticism, often fueled by historical vaccine controversies and the rapid development of novel mRNA technology, continued to generate concerns, particularly regarding long-term outcomes for offspring. A significant component of this hesitancy revolved around unfounded fears that the vaccines might impact fetal neurodevelopment, specifically linking them to autism spectrum disorder (ASD) – a concern that has historically plagued other childhood vaccinations despite overwhelming scientific evidence to the contrary. This latest research directly addresses these specific long-term neurodevelopmental anxieties, offering a comprehensive and reassuring answer.

A Rigorous Investigation: The Maternal-Fetal Medicine Units Network Study

The investigation, a prospective, multi-center, and observational study, was meticulously conducted by researchers within the esteemed Maternal-Fetal Medicine Units (MFMU) Network, a network of academic medical centers funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) that conducts clinical trials and research in maternal-fetal medicine. The study spanned from May 2024 to March 2025, focusing on a critical developmental window for early childhood assessment.

The research team evaluated a cohort of 434 children, all between 18 months and 30 months of age, a period crucial for identifying early signs of autism and other developmental concerns. The cohort was evenly divided: 217 children were born to mothers who had received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within 30 days prior to conception. The remaining 217 children served as a control group, born to mothers who did not receive an mRNA vaccine during or within 30 days prior to pregnancy. This robust comparative design allowed for direct assessment of the vaccine’s potential impact.

Dr. George R. Saade, MD, a senior researcher on the study, Professor and Chair of Obstetrics and Gynecology, and Associate Dean for Women’s Health at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA, underscored the findings. "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine," Dr. Saade stated, emphasizing the consistency of development across both groups.

Methodology: Ensuring Accuracy and Minimizing Bias

To ensure the highest degree of accuracy and minimize potential confounding factors, researchers employed a rigorous matching protocol. Vaccinated mothers were carefully paired with unvaccinated mothers based on several key characteristics: the location of delivery (hospital, birth center, etc.), the precise date of delivery, insurance status, and racial demographics. This meticulous matching aimed to create two highly comparable groups, allowing researchers to isolate the effect of maternal vaccination.

Furthermore, certain pregnancies were excluded from both groups to enhance the homogeneity and relevance of the study population. These exclusions included pregnancies that concluded before 37 weeks of gestation (preterm births), those involving multiple babies (twins, triplets, etc., which often have different developmental trajectories), or those that resulted in a child with a major congenital malformation. By standardizing the cohorts in this manner, the study significantly strengthened the validity of its conclusions regarding neurodevelopmental outcomes.

When the children reached 1 ½ to 2 ½ years of age, their development was comprehensively assessed using a battery of validated screening tools. The primary instrument was the Ages and Stages Questionnaire Version 3 (ASQ-3), a widely recognized and reliable parent-completed screening tool that measures progress in five crucial developmental domains: communication, gross motor skills, fine motor skills, problem-solving, and personal social interaction. To further enrich the developmental profile and identify any subtle differences, the team also reviewed results from the Child Behavior Checklist (CBCL), the Modified Checklist for Autism in Toddlers (M-CHAT), and the Early Childhood Behavior Questionnaire (ECBQ). The combined application of these tools provided a holistic and granular view of each child’s developmental and behavioral patterns.

Dr. Brenna L. Hughes, MD, MSc, Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, commended the study’s rigor. "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy," Dr. Hughes remarked, highlighting the credibility and scientific integrity underpinning the results.

Broader Context and Implications: Reassuring Parents and Informing Public Health

The findings from the SMFM 2026 Pregnancy Meeting study represent a significant milestone in understanding the long-term safety profile of mRNA COVID-19 vaccines in pregnancy. This research directly contributes to a growing body of evidence that systematically debunks fears surrounding vaccine-induced developmental disorders. The prevalence of autism spectrum disorder in the United States, for instance, is estimated to be 1 in 36 children aged 8 years, according to the CDC, and it is crucial that the public understands that this prevalence is not linked to vaccination.

The study’s conclusions carry profound implications for public health messaging and parental decision-making. By conclusively demonstrating no link between maternal mRNA COVID-19 vaccination and childhood neurodevelopmental disorders, including autism, the research provides powerful scientific ammunition against vaccine misinformation campaigns. It reinforces the consistent recommendations from leading health organizations worldwide that emphasize the safety and benefits of COVID-19 vaccination for pregnant individuals.

For expectant parents, these findings offer immense reassurance. The decision to vaccinate during pregnancy is a deeply personal one, often fraught with anxiety, particularly when conflicting information circulates. This study provides a clear, evidence-based answer to a significant concern, empowering parents to make informed choices based on sound scientific data rather than unsubstantiated fears.

Furthermore, the study underscores the importance of continued, robust, long-term research into maternal and infant health outcomes following vaccination. While initial safety data is critical for rapid public health responses, studies like this one, which meticulously follow children into their early developmental years, are invaluable for building comprehensive understanding and public trust.

The funding for this crucial research was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a testament to the National Institutes of Health’s commitment to advancing maternal and child health. The authors noted that while the study was NIH-funded, the conclusions presented are their own and do not necessarily reflect the official views of the National Institutes of Health, adhering to standard scientific disclosure practices.

The full oral abstract, titled "#8 Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," is scheduled for publication in the February 2026 issue of PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine. Its publication will further solidify these findings within the scientific literature, making them accessible to a broader audience of clinicians, researchers, and public health professionals, and ultimately contributing to more informed healthcare decisions globally. This landmark study marks a significant step forward in ensuring the health and well-being of mothers and their children in the post-pandemic era, providing clarity and confidence where once there were questions.